Preliminary clinical observation of unilateral implantation of trifocal intraocular lens Authors: Zhong Chu, Haiwei Chen, JiaWei Song, Zhen Shao, Hongsheng Bi, Dongmei Liu Published: 2026 ABSTRACT AbstractBackgroundEvidence on unilateral trifocal IOL implantation is limited. This study evaluates the clinical outcomes of unilateral implantation of the AcrySof IQ PanOptix TFNT00 trifocal intraocular lens (IOL) in cataract patients.MethodsThis study included 55 eyes of 55 cataract patients who underwent unilateral TFNT00 trifocal IOL implantation. Comprehensive evaluations were performed preoperatively and postoperatively at 1, 3, 6, and 12 months. Outcome measures included uncorrected distance visual acuity (UDVA), uncorrected intermediate visual acuity (UIVA), uncorrected near visual acuity (UNVA), and corrected distance visual acuity (CDVA); defocus curve analysis; objective optical quality parameters, including Strehl ratio (SR) and modulation transfer function area ratio (MTF-AR); reading performance; and dysphotopsia. Subjective visual function was quantified using the VF-14 Cataract Visual Function Questionnaire at 1 and 12 months postoperatively.ResultsAt 12 months postoperatively, 76.4% of eyes achieved UDVA of 20/20 or better and 87.3% achieved a CDVA of 20/20 or better (≤ 0.0 logMAR). All eyes achieved UIVA and UNVA of 20/40 or better (≤ 0.3 logMAR). Refractive outcomes were stable and accurate, with 74.5% of eyes within ± 0.50 D of target spherical equivalent and a mean residual astigmatism of 0.25 ± 0.25 D at 12 months. Defocus curves demonstrated a bimodal profile with peaks at 0.00 to -0.50 D and − 2.00 to -2.50 D. Significant improvements were observed in objective optical quality parameters, Strehl ratio (SR) improved from 0.008 ± 0.007 preoperatively to 0.093 ± 0.023 at 12 months (P < 0.001), and modulation transfer function area ratio (MTF-AR) increased from 0.169 ± 0.060 to 0.413 ± 0.077 (P < 0.001). Reading performance showed marked enhancement in both reading acuity and speed (both P < 0.001). VF-14 questionnaire scores exceeded 3 points for all items. Glare or halos were reported by 3 eyes (5.5%) at 12 months; severity was not formally graded.ConclusionUnilateral implantation of the TFNT00 trifocal IOL effectively restores distance, intermediate, and near vision in cataract patients, with favorable objective optical quality and a low incidence of photic phenomena. Patients reported satisfactory subjective visual function across a wide range of daily activities, suggesting effective neuroadaptation despite monocular correction. These preliminary findings support unilateral trifocal IOL implantation as a viable option for patients in whom bilateral surgery is not feasible or desired. However, given the exploratory nature of this study, further comparative research with larger cohorts is warranted to confirm these outcomes.Keywords: Cataract, Trifocal Intraocular lens, Visual acuity, Visual quality Introduction Cataracts remain a leading global cause of blindness and visual impairment. Phacoemulsification combined with intraocular lens (IOL) implantation represents the predominant treatment modality [1]. Driven by societal progress and heightened patient expectations for visual quality, cataract surgery has transitioned from a vision-restoring procedure to a refractive intervention [2]. Postoperative demands now extend beyond monofocal distance vision restoration to encompass the reconstruction of full-range visual function, including distance, intermediate, and near vision [3]. While monofocal IOLs effectively improve distance vision, their fixed focal point inherently limits their ability to meet intermediate and near visual demands, resulting in significant postoperative spectacle dependence [4]. In contrast, trifocal IOLs are designed to provide functional vision across all distances (distance, intermediate, and near), offering visual quality approximating that of the natural crystalline lens. This presents a promising solution for enhancing postoperative visual quality and reducing spectacle reliance [5]. Current clinical research predominantly focuses on visual outcomes following bilateral multifocal IOL implantation. However, unilateral implantation is a frequent clinical necessity, applicable in various scenarios such as unilateral cataract (e.g., secondary to high myopia or inflammation) or when the fellow eye possesses good vision, corneal opacity, amblyopia, or other conditions precluding or not requiring IOL implantation. Critically, for patients with unilateral cataract receiving a monofocal IOL, although visual acuity may improve in the operated eye, binocular visual function is likely to be compromised. Spectacle correction to compensate for the lack of accommodation in the IOL-implanted eye induces varying degrees of anisometropia and aniseikonia, thereby impairing binocular vision function [6]. This study specifically investigates the clinical outcomes of unilateral implantation of the TFNT00 IOL (AcrySof IQ PanOptix™, Alcon Laboratories, Fort Worth, TX, USA). By comprehensively evaluating visual acuity, defocus curves, objective and subjective visual quality parameters, and the incidence of optical disturbances, we aim to explore the efficacy and patient-reported outcomes of unilateral multifocal IOL implantation. The findings are intended to provide evidence for patients requiring unilateral multifocal IOLs and assist surgeons in optimizing IOL selection strategies. Methods Study design and participants This retrospective study was reviewed and approved by the Ethics Committee of the Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine (HEC-HY-2025013KY). All procedures followed the tenets of the Declaration of Helsinki. A total of 55 eyes from 55 patients (35 males, 20 females) who underwent unilateral implantation of the trifocal TFNT00 IOL at the Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine were enrolled. Patients meeting all the following criteria were included: (1) Diagnosis of cataract with significant visual impairment in one eye, scheduled for phacoemulsification combined with IOL implantation. (2) Absence of significant retinal pathology, confirmed by optical coherence tomography (OCT) and fundus photography. (3) Commitment to and completion of the scheduled postoperative follow-up visits. (4) Successful and uncomplicated surgical procedure without posterior capsule rupture or lens dislocation. Patients were excluded based on any of the following criteria: (1) Presence of glaucoma, chronic uveitis, corneal diseases (opacity, degeneration, dystrophy), history of ocular surgery or trauma leading to zonular weakness, iris or lens capsule defects, previous retinal surgery, retinal pathologies (macular diseases, diabetic retinopathy), or any optic nerve pathology.(2) History of amblyopia.(3) Corneal astigmatism ≥ 0.75 diopters (D).(4) Traumatic cataract or congenital cataract.(5) Inability to complete the required follow-up schedule. Intraocular lens The IOL is a multifocal, foldable lens that filters ultraviolet and blue light. It features a one-piece design comprising a central optic and two open-loop haptics. The optic is made of a proprietary hydrophobic acrylic material incorporating a blue-light-filtering chromophore. This chromophore provides filtering within the 400–475 nm blue light wavelength range, mimicking the natural human crystalline lens. The IOL has an optic diameter of 6.0 mm and an overall diameter of 13.0 mm. A diffractive structure, located within the central 4.5 mm of the optic, splits incoming light to provide + 2.17 D of add power for intermediate vision and + 3.25 D of add power for near vision. Preoperative examination Comprehensive preoperative assessments included: uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA) at 4 m, uncorrected intermediate visual acuity (UIVA) at 60 cm, and uncorrected near visual acuity (UNVA) at 40 cm; intraocular pressure measurement; slit-lamp biomicroscopy for anterior segment evaluation; IOL Master 700 (Carl Zeiss Meditec AG, Germany) biometry; fundus photography; ocular B-scan ultrasonography; macular optical coherence tomography (OCT); OPD-Scan III (Nidek Co., Ltd., Japan) for refractive status and objective visual quality analysis; lacrimal duct irrigation; reading ability assessment. Glaucoma was excluded based on intraocular pressure measurement and optic nerve head assessment using optical coherence tomography (OCT). Patient-reported visual function was assessed using the VF-14 (Cataract Patient Functional Questionnaire), a validated instrument for measuring functional impairment due to cataracts [7]. Surgical technique All procedures were performed by a single experienced cataract surgeon. On the day of surgery, vital signs were monitored for all enrolled patients. Preoperative preparation commenced 30 min prior to surgery: pupillary dilation was achieved using compound tropicamide eye drops (Zhuobi’an, Shenyang Xingqi Eye Medicine Co., Ltd., China), followed by topical anesthesia with 0.4% oxybuprocaine hydrochloride eye drops (Benoxil, Santen Pharmaceutical Co., Ltd., Japan) administered three times at 5-minute intervals. All procedures were performed by a single experienced cataract surgeon. On the day of surgery, vital signs were monitored for all enrolled patients. Preoperative preparation commenced 30 min prior to surgery: pupillary dilation was achieved using compound tropicamide eye drops (Zhuobi’an, Shenyang Xingqi Eye Medicine Co., Ltd., China), followed by topical anesthesia with 0.4% oxybuprocaine hydrochloride eye drops (Benoxil, Santen Pharmaceutical Co., Ltd., Japan) administered three times at 5-minute intervals. With the patient in the supine position, standard aseptic draping was performed. An eyelid speculum was placed. The conjunctival sac was irrigated with balanced salt solution. After verifying proper function of the phacoemulsification system (Centurion Vision System, Alcon Laboratories, Inc., USA), surgery commenced. A 2.5 mm clear corneal incision was created at the steep corneal axis. Viscoelastic material (sodium hyaluronate 1.0%) was injected into the anterior chamber. Continuous curvilinear capsulorhexis was performed using capsulorhexis forceps, achieving a capsular opening diameter of approximately 5.0–5.5 mm. A paracentesis was made at the clear corneal limbus. Thorough hydrodissection and hydrodelineation were performed. The lens nucleus was emulsified using phacoemulsification, followed by aspiration of residual lens cortex. Posterior capsule polishing was performed. Additional viscoelastic was injected. The TFNT00 trifocal IOL was implanted into the capsular bag and positioned to ensure centration of the optic. Residual viscoelastic material was aspirated using an irrigation/aspiration (I/A) handpiece. The corneal incisions were hydrated to ensure watertight closure. A topical combination of tobramycin and dexamethasone eye drops was instilled into the conjunctival sac. Surgery was then completed. With the patient in the supine position, standard aseptic draping was performed. An eyelid speculum was placed. The conjunctival sac was irrigated with balanced salt solution. After verifying proper function of the phacoemulsification system (Centurion Vision System, Alcon Laboratories, Inc., USA), surgery commenced. A 2.5 mm clear corneal incision was created at the steep corneal axis. Viscoelastic material (sodium hyaluronate 1.0%) was injected into the anterior chamber. Continuous curvilinear capsulorhexis was performed using capsulorhexis forceps, achieving a capsular opening diameter of approximately 5.0–5.5 mm. A paracentesis was made at the clear corneal limbus. Thorough hydrodissection and hydrodelineation were performed. The lens nucleus was emulsified using phacoemulsification, followed by aspiration of residual lens cortex. Posterior capsule polishing was performed. Additional viscoelastic was injected. The TFNT00 trifocal IOL was implanted into the capsular bag and positioned to ensure centration of the optic. Residual viscoelastic material was aspirated using an irrigation/aspiration (I/A) handpiece. The corneal incisions were hydrated to ensure watertight closure. A topical combination of tobramycin and dexamethasone eye drops was instilled into the conjunctival sac. Surgery was then completed. Postoperative assessment Patients underwent follow-up examinations at 1, 3, 6, and 12 months postoperatively. Assessments included: UDVA, CDVA, UIVA (60 cm), and UNVA (40 cm); defocus curve plotting; and objective visual quality analysis using the OPD ScanIII to measure Strehl Ratio (SR) and Modulation Transfer Function Area Ratio (MTF-AR) in the operated eye. Reading performance was evaluated using standardized Chinese Radner reading charts. Chart illumination was maintained at approximately 140 lx. Testing was performed at a reading distance of 40 cm. Reading acuity was recorded as the smallest legible print size (in points, pt.). Reading speed was calculated based on the time required to read one page of text (30 characters per page), expressed as words per minute (wpm): Reading Speed (wpm) = 30 / (reading time in seconds / 60). Subjective visual function was assessed using the validated Chinese version of the VF-14 Cataract Visual Function Questionnaire. The questionnaire comprises 14 items evaluating difficulty in performing daily activities commonly affected by cataracts. Each item is scored based on reported difficulty: 4 points (no difficulty), 3 points (mild difficulty), 2 points (moderate difficulty), 1 point (severe difficulty), and 0 points (unable to perform the activity). Dysphotopsia (e.g., glare, halos) was assessed through a non-standardized, open-ended interview at each follow-up visit. Patients were asked whether they had noticed any new visual phenomena such as glare, halos, or starbursts around lights. If present, the symptom was recorded, but its severity was not graded using a validated scale. Statistical analysis Statistical analyses were performed using SPSS version 29.0 (IBM Corp., Armonk, NY, USA). Normality of continuous variables was assessed using the Shapiro–Wilk test. Data are presented as mean ± standard deviation (SD), with 95% confidence intervals (CIs) reported for key outcome measures where appropriate. Repeated-measures analysis of variance (ANOVA) was used to compare visual acuity, optical quality parameters, and reading performance across multiple time points (preoperative, 1, 3, 6, and 12 months). Mauchly’s test of sphericity was conducted, and if violated, the Greenhouse–Geisser correction was applied to adjust the degrees of freedom. Post-hoc pairwise comparisons were performed using the Bonferroni correction. For defocus curve analysis, the mean visual acuity across all defocus levels was calculated for each patient at each time point and compared using one-way repeated measures ANOVA, with the same sphericity assessment and correction methods applied. P value < 0.05 was considered statistically significant. A prospective power analysis was not performed due to the retrospective nature of the study. Results This study included 55 patients (55 eyes) with cataract who underwent unilateral implantation of the AcrySof IQ PanOptix trifocal IOL. All surgeries were uneventful, with no significant intraoperative or postoperative complications. All participants completed the follow-up protocol. The cohort comprised 35 males and 20 females. Mean patient age was 56.87 ± 8.94 years, mean axial length was 24.28 ± 1.36 mm, and mean implanted IOL power was 19.13 ± 3.26D (Table 1). Table 1Demographics and preoperative visual acuity (n = 55)ParametersValue (Mean ± SD) or n (%)Gender Female20(36.4) Male35(63.6)Age, (years)56.87 ± 8.94Axial Length, (mm)24.28 ± 1.36Implanted Trifocal IOL Power, (D)19.13 ± 3.26Preoperative visual acuity (logMAR) UDVA0.56 ± 0.30 CDVA0.44 ± 0.23 UIVA0.71 ± 0.25 UNVA0.66 ± 0.24IOL = intraocular lens; UDVA = uncorrected distance visual acuity; CDVA = corrected distance visual acuity; UIVA = uncorrected intermediate visual acuity; UNVA = uncorrected near visual acuity; D = diopters Demographics and preoperative visual acuity (n = 55) IOL = intraocular lens; UDVA = uncorrected distance visual acuity; CDVA = corrected distance visual acuity; UIVA = uncorrected intermediate visual acuity; UNVA = uncorrected near visual acuity; D = diopters Visual acuity Postoperative visual acuity improved significantly across all distances and remained stable throughout the 12-month follow-up period. All patients achieved uncorrected distance visual acuity (UDVA), uncorrected intermediate visual acuity (UIVA) at 60 cm, and uncorrected near visual acuity (UNVA) at 40 cm of 20/40 or better (≤ 0.3 logMAR) at all postoperative visits. At 12 months postoperatively, 76.4% (42/55; 95% CI: 65.1% to 87.6%) of eyes achieved UDVA of 20/20 or better (≤ 0.0 logMAR), and 87.3% (48/55; 95% CI: 78.5% to 96.1%) achieved CDVA of 20/20 or better. For intermediate and near vision, the proportions achieving 20/20 or better at 12 months were 69.1% (38/55; 95% CI: 56.7% to 81.5%) for UIVA and 67.3% (37/55; 95% CI: 54.8% to 79.8%) for UNVA. Distance vision reached excellent levels by 1 month and remained stable thereafter. Intermediate and near vision showed progressive improvement during the first 6 months postoperatively—UIVA increasing from 54.6% at 1 month to 69.1% at 12 months, and UNVA from 58.2% to 67.3%—before stabilizing by 12 months (Fig. 1). These outcomes demonstrate that unilateral TFNT00 trifocal IOL implantation effectively restores functional vision across all distances. Cumulative Snellen visual acuity curves at (A)1 month, (B)3 months, (C) 6 months, and (D) 12 months postoperatively Refractive outcomes Postoperative refraction was stable throughout the follow-up period. At 12 months postoperatively, the mean spherical equivalent was + 0.11 ± 0.45 D (95% CI: -0.01 to + 0.23 D). The cumulative proportions of eyes within ± 0.25 D, ± 0.50 D, and ± 1.00 D of emmetropia were 43.6% (24/55; 95% CI: 30.5% to 57.1%), 74.5% (41/55; 95% CI: 63.0% to 86.0%), and 98.2% (54/55; 95% CI: 94.7% to 100%), respectively. Only one eye (1.8%; 95% CI: 0% to 5.3%) had a spherical equivalent outside ± 1.00 D. The mean residual refractive cylinder was 0.25 ± 0.25 D (95% CI: 0.18 to 0.32 D), with 92.7% (51/55; 95% CI: 85.9% to 99.6%) of eyes having ≤ 0.50 D of residual astigmatism (Table 2). Table 2Postoperative spherical equivalent distribution at 12 months (n = 55)Spherical Equivalent RangeEyes, n (%)95% CIWithin ± 0.25 D24 (43.6%)30.5% to 57.1%Within ± 0.50 D41 (74.5%)63.0% to 86.0%Within ± 1.00 D54 (98.2%)94.7% to 100%Outside ± 1.00 D1 (1.8%)0% to 5.3%D = diopters Postoperative spherical equivalent distribution at 12 months (n = 55) D = diopters Defocus curve The defocus curve at 1 month postoperatively demonstrated peak visual acuity between 0.00 D and − 0.50 D, maintained high acuity levels across the − 1.00 D to -2.00 D range, and exhibited a secondary acuity peak at -2.00 D to -2.50 D. Comparative analysis revealed significantly higher visual acuity values in the 3-month curve compared to the 1-month curve (P < 0.001). Furthermore, the 6-month and 12-month defocus curves showed no significant difference relative to the 3-month curve (P > 0.05). Across all follow-up time points, the defocus curves consistently indicated that unilateral TFNT00 trifocal IOL implantation provides excellent and sustained visual quality over a defocus range of 0.00 D to -2.50 D, effectively addressing patients’ visual demands for distance, intermediate, and near vision (Fig. 2). Graph showing Unilateral defocus during the follow-up. D=diopter; logMAR =logarithm of the minimum angle of resolution Objective visual quality and reading performance Postoperatively, patients exhibited significant improvements in both reading ability and objective visual quality. Reading acuity decreased from 21.05 ± 7.58pt (95% CI: 18.99 to 23.11 pt) preoperatively to 6.29 ± 1.41pt (95% CI: 5.91 to 6.67 pt) at 1 month (P < 0.001), with further improvement observed by 12 months (5.55 ± 0.86pt; 95% CI: 5.32 to 5.78 pt). Reading speed (words/min) increased from 128.58 ± 14.94 (95% CI: 124.54 to 132.62 wpm) preoperatively to 156.98 ± 28.00 (95% CI: 149.40 to 164.56 wpm) at 1 month (P < 0.001), peaked at 164.36 ± 29.09 (95% CI: 156.27 to 172.45 wpm) by 3 months, and showed no significant differences between 3, 6, and 12 months (P > 0.05). Regarding objective optical quality assessed by the OPD-Scan III, both Strehl ratio (SR) and modulation transfer function area ratio (MTF-AR) demonstrated significant increases compared to preoperative values at all postoperative time points (P < 0.001). SR improved from 0.008 ± 0.007 (95% CI: 0.006 to 0.010) preoperatively to 0.066 ± 0.041 (95% CI: 0.055 to 0.077) at 1 month and reached 0.093 ± 0.023 (95% CI: 0.087 to 0.099) by 12 months. MTF-AR increased from 0.169 ± 0.060 (95% CI: 0.153 to 0.185) preoperatively to 0.340 ± 0.104 (95% CI: 0.312 to 0.368) at 1 month, reached 0.404 ± 0.090 (95% CI: 0.380 to 0.428) at 3 months, and achieved 0.413 ± 0.077 (95% CI: 0.393 to 0.433) at 12 months. All parameters showed substantial improvement by 1 month postoperatively, entered a plateau phase between 3 and 6 months, and remained stable throughout the 12-month follow-up period (Table 3). The high level of reading performance achieved underscores the effective restoration of functional near vision under monocular viewing condition. Table 3Reading ability and objective visual quality (n = 55)ParametersPreoperativePostoperative1Month3Month6Month12Month Reading Ability Reading Acuity (pt.)21.05 ± 7.586.29 ± 1.415.85 ± 0.975.58 ± 0.965.55 ± 0.86Reading Speed (wpm)128.58 ± 14.94156.98 ± 28.00164.36 ± 29.09158.67 ± 28.30164.78 ± 29.87 Objective Visual Quality SR (Strehl Ratio)0.008 ± 0.0070.066 ± 0.0410.087 ± 0.0260.087 ± 0.0220.093 ± 0.023MTF-AR (Area Ratio)0.169 ± 0.0600.340 ± 0.1040.404 ± 0.0900.416 ± 0.0900.413 ± 0.077pt = points; wpm = words per minute; MTF = modulation transfer function; AR =area ratio Reading ability and objective visual quality (n = 55) pt = points; wpm = words per minute; MTF = modulation transfer function; AR =area ratio VF-14 visual function questionnaire VF-14 Visual Function Questionnaire assessment demonstrated significant and sustained improvements from preoperative baseline levels across all activity categories. Functional stability analysis between 1 and 12 months postoperatively indicated that the vast majority of vision-related activities achieved stability early after surgery and were maintained through the first year. Among the 14 activity categories, scores for 11 (78.6%) showed no statistically significant difference (P > 0.05) between the 1 month and 12 months, including activities such as reading newspapers/books, recognizing people up close, seeing steps/curbs, and completing forms/checks. However, scores at 12 months postoperatively showed significant improvement compared to 1 month for three specific activities: reading small print (e.g., medicine bottle labels, phone books; 3.45 ± 0.57 vs. 3.76 ± 0.43, P < 0.001), performing fine handiwork (e.g., sewing, knitting, carpentry; 3.36 ± 0.76 vs. 3.55 ± 0.63, P = 0.018), and driving at night (3.60 ± 0.69 vs. 3.85 ± 0.41, P = 0.004). These results indicate that implantation of the TFNT00 IOL provides effective visual function recovery, delivering consistent and stable improvements for a wide range of daily living activities throughout the first postoperative year, although activities demanding high visual precision or occurring under low illumination may require longer adaptation periods for full functional recovery (Table 4). The high VF-14 scores across most daily tasks indicate that patients achieved satisfactory subjective visual function and functional independence following unilateral implantation. Table 4Mean values of VF-14 questionnaire categories in patients (n = 55)VF-14 categoriesPreoperativeMonth1Month121.Reading small print, such as medicine bottle labels, a telephone book, or food labels1.09 ± 0.873.45 ± 0.573.76 ± 0.43ab2.Reading a newspaper or a book1.38 ± 0.793.89 ± 0.313.87 ± 0.343.Reading a large-print book or large-print newspaper or numbers on a telephone1.47 ± 0.773.82 ± 0.433.82 ± 0.434.Recognizing people when they are close to you2.16 ± 0.743.96 ± 0.193.96 ± 0.195.Seeing steps, stairs or curbs1.82 ± 0.833.95 ± 0.233.96 ± 0.196.Reading traffic signs, street signs or store signs1.49 ± 0.753.85 ± 0.403.89 ± 0.317.Doing fine handwork like sewing, knitting, crocheting, carpentry0.18 ± 0.393.33 ± 0.103.55 ± 0.85b8.Writing checks or filling out forms1.38 ± 0.743.85 ± 0.363.85 ± 0.369.Playing games such as bingo, dominos, card games, or mahjong1.47 ± 0.883.87 ± 0.343.91 ± 0.2910.Taking part in sports like bowling, handball, tennis, golf1.69 ± 0.783.93 ± 0.263.95 ± 0.2311.Cooking2.33 ± 0.673.96 ± 0.193.98 ± 0.1312.Watching television2.02 ± 0.793.82 ± 0.393.91 ± 0.2913.Driving during the day1.40 ± 0.853.78 ± 0.423.84 ± 0.3714.Driving at night1.02 ± 0.883.60 ± 0.683.85 ± 0.40ba P < 0.001, Month 12 vs. Month 1;b P < 0.05, Month 12 vs. Month 1VF-14: National eye institute visual function-14 questionnaire. Grading scores: 4 points: No difficulty, 3 points: Mild difficulty, 2 points: Moderate difficulty, 1 point: Severe difficulty, 0 point: Unable to perform Mean values of VF-14 questionnaire categories in patients (n = 55) a P < 0.001, Month 12 vs. Month 1;b P < 0.05, Month 12 vs. Month 1 VF-14: National eye institute visual function-14 questionnaire. Grading scores: 4 points: No difficulty, 3 points: Mild difficulty, 2 points: Moderate difficulty, 1 point: Severe difficulty, 0 point: Unable to perform Reasons for unilateral surgery Analysis of indications for unilateral surgery revealed that the predominant reason, accounting for 56.4% (31/55) of cases, was patient preference for an adaptation period combined with adequate UDVA ≤ 0.1 logMAR in the contralateral eye. Other indications included adequate CDVA ≤ 0.1 logMAR in the fellow eye (27.3%, 15/55), significant retinal/macular dysfunction (9.1%, 5/55), corneal opacity (3.6%, 2/55), amblyopia (1.8%, 1/55), and no light perception (1.8%, 1/55) (Fig. 3). Distribution of contralateral eye status in patients after unilateral TFNT00 IOL implantation Postoperative dysphotopsia Consistent with the known optical profile of multifocal IOLs, which are associated with a higher incidence of dysphotopsia compared to monofocal IOLs, a subset of patients in this study reported these phenomena following unilateral TFNT00 implantation. The proportion of patients experiencing dysphotopsia decreased progressively over the 12-month follow-up period: 25.5% (14/55; 95% CI: 14.7% to 39.0%) at 1 month, 21.8% (12/55; 95% CI: 11.9% to 34.3%) at 3 months, 9.1% (5/55; 95% CI: 3.0% to 19.0%) at 6 months, and 5.5% (3/55; 95% CI: 1.1% to 14.2%) at 12 months. This trend indicates significant reduction in reported symptoms over time, with the vast majority of patients demonstrating adaptation within the first year. Discussion The development of multifocal IOL aims to reduce spectacle dependence following cataract surgery. While bifocal IOL provide satisfactory visual function at distance and near, they often fail to meet patient expectations at intermediate distances [8]. To address this limitation, trifocal IOL incorporate an intermediate focal point optimized for functional vision. The TFNT00 IOL utilizes apodized diffractive technology with a progressive step design, setting its intermediate focus at 60 cm—corresponding to natural arm length—which better accommodates contemporary visual demands (e.g., electronic device use and dashboard viewing) compared to conventional trifocal IOLs with 80-cm intermediate focus [9, 10]. Clinical evidence demonstrates favorable refractive outcomes and visual performance with TFNT00 IOL implantation [11, 12]. While most studies evaluating multifocal IOL involve bilateral implantation, limited data exist regarding unilateral applications. Levinger et al. reported that presbyopic emmetropes receiving unilateral FineVision Micro F trifocal IOLs achieved UDVA of 0.18 ± 0.32 logMAR (20/30 Snellen), UIVA of 0.17 ± 0.21 logMAR (20/30 Snellen), and UNVA of 0.02 ± 0.10 logMAR (20/21 Snellen) at 6 months, providing functional vision across distances [13]. Conversely, Liu et al. found that unilateral SBL-3 multifocal IOL implantation yielded satisfactory distance vision and patient satisfaction, though intermediate/near vision was inferior to bilateral implantation [14]. Yoon et al., however, observed no significant differences in visual acuity, satisfaction, spectacle independence, or visual symptoms between unilateral Tecnis ZM900 implantation and hybrid bilateral implantation (Tecnis ZM900 + Rezoom NXG1) [15]. Collectively, these studies suggest that the functional outcomes and patient satisfaction following unilateral multifocal IOL implantation may be influenced by the specific optical design of the IOL. Our study demonstrates significant visual improvement after unilateral TFNT00 IOL implantation. Patients achieved favorable clinical outcomes across all distances: at 12 months, 76.4% achieved UDVA and 87.3% achieved CDVA of 20/20 or better, while functional vision of 20/40 or better was achieved in 100% for UIVA and UNVA. These findings are consistent with Ozturkmen et al., who documented high satisfaction following unilateral TFNT00 implantation [16]. Although not all patients achieved CDVA of 20/20 (87.3% at 12 months), this proportion is consistent with published benchmarks for the TFNT00 IOL, which report 88% achieving this level in large cohorts [17]. The slight variability in our cohort is likely attributable to clinically relevant factors, including subclinical age-related macular changes, tear film instability, and individual differences in neuroadaptation. In addition to the excellent visual acuity outcomes, the refractive results in this cohort demonstrated high predictability and stability. At 12 months postoperatively, 74.5% of eyes were within ± 0.50 D of the target refraction, and 98.2% were within ± 1.00 D, with a mean residual astigmatism of 0.25 ± 0.25 D. These values are consistent with previous studies evaluating the TFNT00 IOL, which have reported similar accuracy in achieving emmetropia [18, 19]. The precise refractive correction achieved in our patients likely contributed to the observed high levels of visual performance and patient satisfaction. Moreover, the low residual astigmatism (≤ 0.50 D in 92.7% of eyes) minimized the potential for cylindrical defocus that could degrade visual quality, particularly at intermediate and near distances. These findings underscore the importance of meticulous preoperative biometry and surgical technique in optimizing refractive outcomes with multifocal IOL. To assess the restoration of full-range vision, defocus curve testing was employed, providing insight into visual performance outside the primary focal points. Our data revealed a distinct bimodal defocus curve profile, with peaks at 0.00D to -0.50D and 2.00D to -2.50D. This pattern is consistent with the two peaks typically observed in bifocal IOL defocus curves; however, bifocal IOLs exhibit a significant decline in visual acuity within the intermediate range (0.00D to -2.50D) [20, 21]. In contrast, the present study demonstrated consistently excellent visual acuity (< 0.15 logMAR) between the two peaks of the TFNT00 IOL curve, indicating more continuous performance across intermediate distances. Torky et al. reported similar findings for bilateral TFNT00 implantation, with best visual acuities at 0.00D (-0.04 logMAR) and − 2.00D (0.01 logMAR), followed by a gradual decline with increasing negative defocus [22]. Our results suggest that unilateral TFNT00 IOL implantation also provides good intermediate visual acuity, with near vision acuity consistently better than 0.50 logMAR, resulting in an overall smooth defocus curve. Patients demonstrated significant improvement in reading performance with effective spectacle independence, consistent with findings by Mencucci et al. [23].Objective assessment of optical quality at 12 months revealed statistically significant enhancements in SR and AR compared to preoperative values (P < 0.001), confirming substantial visual quality improvement following unilateral TFNT00 IOL implantation. Subjective evaluation using the validated VF-14 questionnaire showed markedly higher scores for spectacle-independent distance tasks postoperatively. While some patients reported mild difficulty with fine near-vision activities (e.g., reading medication labels) and night driving as primary concerns, significant improvement was observed at the 12-month assessment. Overall patient satisfaction remained high, confirming that recipients of unilateral TFNT00 IOL can perform daily activities without spectacle correction, thereby substantially enhancing quality of life. A notable finding of this study is the high level of patient-reported satisfaction and functional independence following unilateral implantation, as reflected in the VF-14 scores and reading performance. Despite only one eye receiving the trifocal IOL, patients reported minimal difficulty with a wide range of daily activities, including near tasks like reading. This suggests that effective neuroadaptation may allow the brain to preferentially utilize input from the multifocal IOL-implanted eye for specific tasks while suppressing conflicting input from the fellow eye, resulting in a functionally satisfactory binocular experience. Postoperative photic phenomena are commonly reported with multifocal IOLs. Ramamurthy et al. observed 86.6% of patients reported either no or only occasional halo phenomena; all symptomatic cases except one were mild in severity [24]. In a long-term comparative study assessing visual quality following bilateral implantation of two distinct trifocal intraocular lens designs (FineVision and TFNT00), halo phenomena were reported by 60% (18/30) of patients implanted with the TFNT00 IOL. Notably, only one subject described the intensity of halos as beyond mild severity [25]. Similar findings of glare/halo symptoms have been reported across studies [26, 27]. In our cohort, photic phenomena were present in 25.5% (14/55) of patients during follow-up, progressively decreasing to 5.5% (3/55) at 12 months. This decreasing trend aligns with the known process of neuroadaptation. The lower incidence in our study may be attributable to unilateral implantation, where monocular symptoms likely demonstrate lower subjective impact compared to bilateral manifestations. It is important to note that our assessment was based on unstructured interviews rather than a validated questionnaire, which may introduce recall bias and limit granularity of severity grading. Limitations This study has several limitations. First, its retrospective, single-arm design without a control group precludes direct comparative conclusions. Second, a formal sample size calculation was not performed; the cohort comprised consecutive eligible patients, limiting generalizability. Third, binocular visual function was not assessed using objective measures such as binocular defocus curves or stereopsis tests. Fourth, dysphotopsia assessment was based on non-standardized interviews. Finally, the 12-month follow-up may not capture longer-term changes. Future prospective, randomized controlled trials with larger, predetermined sample sizes and standardized outcome measures are warranted to confirm these findings. Conclusion This preliminary study demonstrates that unilateral implantation of the TFNT00 trifocal intraocular lens effectively restores functional vision across distance, intermediate, and near ranges in carefully selected cataract patients. The procedure yielded favorable visual acuity outcomes, significant improvements in objective optical quality parameters, and high patient-reported satisfaction, with a low and decreasing incidence of photic phenomena over 12 months. The satisfactory subjective visual function reported suggests effective neuroadaptation despite monocular correction. These findings support unilateral trifocal IOL implantation as a viable option for patients in whom bilateral surgery is not feasible or desired. However, given the exploratory nature of this study, the results should be interpreted with caution. Prospective comparative studies with larger cohorts are warranted to definitively establish the role of unilateral trifocal IOL implantation in clinical practice. Acknowledgements Not applicable. Author contributions ZC, HWC, HSB, and DML conceived and designed the study. ZC, HWC, and JWS acquired and analyzed the data. ZC and HWC drafted the manuscript. ZS, HSB and DML critically revised the manuscript for important intellectual content. All authors read and approved the final version of the manuscript. Funding Shandong Province Medicine and Health Science and Technology Program (202407021364). *Zhong Chu is a Master’s candidate in Ophthalmology at Shandong University of Traditional Chinese Medicine. Data availability All the data supporting the findings is contained within the manuscript. Declarations Ethics approval and consent to participate This study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine (Approval No: HEC-HY-2025013KY). The need for informed consent was waived by the same ethics committee due to the retrospective nature of this study, which involved the analysis of anonymized clinical data. Consent for publication Not applicable. Disclosures All the authors have no financial or proprietary interest in any material or method mentioned. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Hongsheng Bi, Email: hongshengbi1@163.com. Dongmei Liu, Email: 13854191223@163.com. References Associated Data Data Availability Statement All the data supporting the findings is contained within the manuscript.